Eli Lilly has acquired 4E Therapeutics, the second non‑opioid pain biotech it has bought in little over a year, strengthening its chronic pain pipeline with experimental once‑daily oral pain candidates for neuropathic pain, migraine and acute pain; and the FDA has set a Prescription Drug User Fee Act (PDUFA) action date of February 2, 2027 for Gilead’s once‑weekly oral Yeztugo (lenacapavir) 300‑mg tablet as a potential long‑acting oral PrEP pill for HIV prevention. Sources: 4E Therapeutics Acquired by Lilly to Advance Non-Opioid Approach ... Lilly buys non-opioid pain drugmaker 4E | BioPharma Dive Lilly to expand its pain pipeline with acquisition of SiteOne ... Eli Lilly to buy Watertown biotech Orna Therapeutics for $2.4 billion Lilly lands next-gen pain asset in $1B SiteOne acquisition Clinical Guidance for PrEP | HIV Nexus - CDC Eli Lilly Acquires Ventyx for $1.2B: Expanding in NLRP3 Space 4E Therapeutics Acquired by Lilly to Advance Non-Opioid Approach to Chronic...
- Get link
- X
- Other Apps